Cargando…

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential

Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy. The MM cells reside in the bone marrow (BM), where reciprocal interactions with the BM niche foster MM cell survival, proliferation, and drug resistance. As in most cancers, the insulin-like growth factor (IGF) system has been d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bieghs, Liesbeth, Johnsen, Hans E., Maes, Ken, Menu, Eline, Van Valckenborgh, Els, Overgaard, Michael T., Nyegaard, Mette, Conover, Cheryl A., Vanderkerken, Karin, De Bruyne, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217049/ https://www.ncbi.nlm.nih.gov/pubmed/27129151 http://dx.doi.org/10.18632/oncotarget.8982

Ejemplares similares

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Exosomes in multiple myeloma: from bench to bedside
por: Menu, Eline, et al.
Publicado: (2022)

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
por: De Veirman, Kim, et al.
Publicado: (2015)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model
por: Nur, Haneen, et al.
Publicado: (2013)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
por: Fan, Rong, et al.
Publicado: (2022)

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2017)

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2018)

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment
por: Duvefelt, Charlotte Fristedt, et al.
Publicado: (2015)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
por: Favreau, Mérédis, et al.
Publicado: (2016)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_00ah28b344tv8l89b76h28j91b